Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 04/02/24
End: 05/13/24
Due: 05/13/25
Phase: N/A
Priority: Normal
Start: 08/01/23
End: 09/30/26
Due: 09/30/27
Phase: N/A
Priority: Normal
Start: 12/01/23
End: 12/31/25
Due: 12/31/26
Phase: N/A
Priority: Normal
Start: 08/09/23
End: 09/06/23
Due: 09/06/24
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Relative Bioavailability and Effect of Food Study With AGMB-129 in Healthy Participants | NCT06397508 | Agomab Spain S.L. | user2@example.com | None | 2024-04-02 | 2024-05-13 | 2025-05-13 | - | - | 2025-07-14 |
| STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease | NCT05843578 | Agomab Spain S.L. | user2@example.com | None | 2023-08-01 | 2026-09-30 | 2027-09-30 | - | - | 2025-07-14 |
| Phase I Study to Assess Safety, Tolerability, PK and PD of AGMB-447 in Healthy Participants and Participants With IPF | NCT06181370 | Agomab Spain S.L. | user2@example.com | None | 2023-12-01 | 2025-12-31 | 2026-12-31 | - | - | 2025-07-14 |
| Drug-Drug Interaction Study With AGMB-129 and Midazolam in Healthy Participants | NCT05937386 | Agomab Spain S.L. | user2@example.com | None | 2023-08-09 | 2023-09-06 | 2024-09-06 | - | - | 2025-07-14 |